Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pr...

Iptacopan showed a statistically significant, clinically meaningful proteinuria reduction in addition to RAAS inhibitors and immunosuppression at 6 months. Iptacopan was well tolerated with an accepta...

g diuretic resistance mechanism could optimize diuretic response. Methods: Patients hospitalized with heart failure and diuretic resistance (6-hour cumulative natriuresis <100 mmol after IV loop di...

Aspirin reduces the incidence of colorectal adenoma and colorectal cancer among high-risk persons. Observational studies suggest that aspirin may also improve disease-free survival after diagnosis,...

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medicati...

In patients with kidney failure on haemodialysis and with high risk of adverse cardiovascular outcomes, spironolactone did not reduce the incidence of major cardiovascular events. The updated meta-ana...

Among patients receiving maintenance dialysis, spironolactone 25 mg daily orally did not reduce the composite outcome of cardiovascular mortality and hospitalisation due to heart failure compared with...

Rituximab, a chimeric monoclonal antibody that targets the CD20 molecule on the surface of B cells, has been part of the therapeutic armamentarium for glomerular diseases since the early 2000s. Over the past decade, it has emerged as a standard-of-care treatment for primary membranous nephropathy (MN) (pMN) and is being increasingly used in steroid-dependent nephrotic syndrome for both pediatric and adult patients.1 The relapsing nature of these renal diseases may require repeated cycles of rituximab to achieve and maintain remission.

The FDA approved pegcetacoplan for treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN in patients age 12 and older.

Summary of the CAPTIVATE platform which will be a twitter spaces discussion